| Document |
Document Title |
|
WO/2023/125486A1 |
Provided are a class of compounds which have a structure as shown in the following general formula (I) and are used as somatostatin receptor subtype 5 (SSTR5) antagonists, and a pharmaceutical composition and the use thereof. The compoun...
|
|
WO/2023/127814A1 |
The present inventors have studied and found that the substituted quinoline derivatives have acetylcholine receptor clustering-inducing action and can be useful as an active ingredient in the pharmaceutical compositions for preventing an...
|
|
WO/2023/130024A1 |
Compounds represented by the Formula below are described in this disclosure. Use, methods, and medicaments related to treatment of conditions or diseases, such as for growing hair in a mammal, are also described herein.
|
|
WO/2023/125908A1 |
Disclosed herein are novel bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation...
|
|
WO/2023/129513A2 |
Disclosed are compounds and pharmaceutically acceptable salts thereof, which are useful as inhibitors nicotinamide N-methyltransferase (NNMT). Also disclosed are pharmaceutical compositions comprising a compound disclosed herein. Related...
|
|
WO/2023/125397A1 |
Provided is a preparation method for an aromatic ring derivative for immune regulation, specifically, provided is a preparation method for a compound of formula (I). A compound shown in formula (I-A) and a compound of formula (I-B) are b...
|
|
WO/2023/126951A1 |
Disclosed herein are inhibitors of autophagy-related protein-protein interactions and their use for treating an autophagy-related disease or disorder, cancer, a cytokine release syndrome (CRS) or a cytokine storm in a subject.
|
|
WO/2023/126336A1 |
The present invention relates to novel bispidine-based compounds comprising at least an optionally substituted ethanoic acid moiety at the N7-position of the bispidine scaffold, said bispidine-based compounds representing metal chelating...
|
|
WO/2023/125935A1 |
The present invention relates to a benzopiperidine derivative regulator, and a preparation method therefor and the use thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation ...
|
|
WO/2023/125841A1 |
A compound of formula (I) as a Polθ inhibitor, a preparation method therefor, and a use thereof.
|
|
WO/2023/125812A1 |
The present application relates to a substituted pyrimidone derivative, and a pharmaceutically acceptable salt, stereoisomer, pharmaceutical composition and medical use thereof. The substituted pyrimidone derivative is a compound having ...
|
|
WO/2023/127783A1 |
The present invention provides a novel compound which has electron transport properties and sufficient solubility with respect to organic solvents. The present invention also provides a novel electrophotographic photoreceptor which makes...
|
|
WO/2023/125947A1 |
The present invention provides a pharmaceutically acceptable salt of a compound as a PRMT5 inhibitor, a crystal form of the pharmaceutically acceptable salt, a preparation method therefor, a pharmaceutical composition comprising the phar...
|
|
WO/2023/124205A1 |
The present application provides organic compounds, an organic electroluminescent device, and an electronic apparatus. The structure of the organic compounds is shown as formula 1, the organic compounds being used in an organic electrolu...
|
|
WO/2023/129963A1 |
The invention is directed to compounds that are active as antibacterial agents. The invention compounds are active against gram-positive and gram-negative bacteria and can be used to treat infections caused by gram-positive and gram-nega...
|
|
WO/2023/129854A1 |
Compounds represented by Formula 1, as depicted herein, are described in this disclosure. Use, methods, and medicaments related to treatment of conditions or diseases, such as for growing hair in a mammal, are also described herein.
|
|
WO/2023/125707A1 |
Disclosed in the present disclosure are a compound as shown in formula I, a racemate, a stereoisomer, a tautomer, an isotope label, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, and a composition thereof, a preparat...
|
|
WO/2023/125737A1 |
The present disclosure provides heterocyclic compounds and use thereof, specially relates to a compound represented by Formula (I), a pharmaceutically acceptable salt thereof, a tautomer thereof, a stereoisomer thereof, a solvate thereof...
|
|
WO/2023/130070A2 |
Provided herein are β-carboline compounds and their use to inhibit dihydroorotate dehydrogenase (DHODH): or a form thereof, wherein R1, R2, R3, R4, Q1, Q2, Q3, Q4, R7, R9, and R11 are as defined herein.
|
|
WO/2023/125276A1 |
Provided in the present invention are an organic compound and a use thereof, the molecular bulk density thereof being improved through the design of the molecular structure, and the compound having excellent hole transport properties; th...
|
|
WO/2023/122322A1 |
The present invention relates to safe and improved processes for the preparation of substantially pure intermediates of formula Va and their use in the synthesis of Ripretinib and salts thereof.
|
|
WO/2023/118092A1 |
The present invention relates to substituted pyrazolo[l,5-a]pyridine-[3,2-e]pyrimidines compounds of formula (I) wherein X, R1, and R2 are as defined in the claims, methods of preparing said compounds, pharmaceutical compositions and com...
|
|
WO/2023/116696A1 |
Disclosed is a methionine adenosyltransferase 2A heterocyclic inhibitor. The structure of the methionine adenosyltransferase 2A inhibitor is represented by general formula I, wherein at most two of W, X, Y and Z are both N, and R1 and R2...
|
|
WO/2023/120696A1 |
The present invention provides a compound that exhibits an anticancer effect based on Checkpoint Kinase 1 (CHK1) inhibition. It is discovered that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof has a ...
|
|
WO/2023/122754A1 |
Provided herein are processes for the streamlined synthesis of Galbulimima alkaloids, such as himbadine, isolated from Galbulimima belgraveana and G. baccatta, trees endemic to the rainforests of Northern Australia and Papua New Guinea, ...
|
|
WO/2023/116920A1 |
A penta- fused hexa-heterocyclic compound, a preparation method, a pharmaceutical composition, and the use. The penta- fused hexa-heterocyclic compound is a compound represented by formula (II) or (III). The compound has an inhibition or...
|
|
WO/2023/116594A1 |
A substituted fused heterocyclic compound, and a preparation method therefor and the use thereof. Provided is a compound having the structure of formula (I) or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutica...
|
|
WO/2023/118011A1 |
A compound of Formula (I') wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
|
|
WO/2023/118875A1 |
The invention relates to a compound of formula (I) which is 6-((1H-pyrazol-4-yl)sulfonyl)-2-((1-cyclopropyl-1H-pyrazol-3
-yl)methyl)phthalazin-1(2H)- one; or a salt and/or solvate thereof; and to its use in treating or preventing an infl...
|
|
WO/2023/118961A1 |
The present disclosure is directed toward drugs and toxins functionalized by at least one saccharide, sulfate or sulfonate; drug conjugates comprising said drugs or toxins and a cleavable linker; and targeted conjugates comprising said d...
|
|
WO/2023/122581A2 |
The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds...
|
|
WO/2023/115142A1 |
This invention relates to compounds of formula (I) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (I) to treat necroptosis and/or inhibit...
|
|
WO/2023/122298A1 |
This invention provides protein stabilizing compounds that have a USP28 Targeting Ligand or USP25 Targeting Ligand, a Protein Targeting Ligand, and optionally a Linker, wherein the Target Protein is ubiquitinated. The protein stabilizing...
|
|
WO/2023/122072A1 |
The present disclosure relates to crystalline forms of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)
-1H-imidazo[4,5-c]pyridin-2(3H)-one free base and HCl salt thereof.
|
|
WO/2023/118250A1 |
The present invention relates to small molecules capable of inhibiting SOS1 (Son of Sevenless) and their salts. Specifically, the present invention relates to heterocyclic compounds of general formula (I) or salts thereof wherein A, X, R...
|
|
WO/2023/122772A1 |
Compounds are provided having the structure of Formula (I): (I) or a pharmaceutically acceptable salt, solvate, hydrate, isomer, or isotope thereof, wherein Ar, X1, X2, R1, R2, R3, and R4 as defined herein. Pharmaceutical compositions co...
|
|
WO/2023/116865A1 |
Provided are a pyrazole-containing derivative, a pharmaceutically acceptable salt thereof, a preparation method therefor and an application thereof. In particular, provided are a compound represented by general formula (I), a pharmaceuti...
|
|
WO/2023/116866A1 |
A five- and six-membered compound, and a preparation method therefor and a pharmaceutical composition and the use thereof. The five- and six-membered compound is a compound as shown in formula I, II or III. The compound has an inhibitory...
|
|
WO/2023/122140A1 |
The present disclosure provides compounds, compositions, and methods useful for inhibiting PARP1, and/or treating a disease, disorder, or condition associated with PARP1, and/or treating cancer.
|
|
WO/2023/116884A1 |
The present disclosure provides a compound represented by structural formula (I) : or a pharmaceutically acceptable salt, or a stereoisomer thereof and their use in, e.g. treating a disease or disorder associated with CDK2. This disclosu...
|
|
WO/2023/122777A1 |
Disclosed herein are oxime compounds having the structure of Formula (I): (I) or a pharmaceutically acceptable salt, solvate, hydrate, isomer, tautomer, racemate, or isotope thereof, wherein R1, R2, R3, R4, R5, R', a, m, and n are as def...
|
|
WO/2023/120331A1 |
In the present invention, an anticancer drug/prodrug is used in a combination therapy with radiotherapy. In the chemical formula representing the same, the moiety in which R1 and R2 are bonded to an N atom results from the removal of an ...
|
|
WO/2023/121413A1 |
The present invention relates to: a novel bicyclic heterocyclyl compound which has an SOS1 inhibitory activity and thus may be utilized for preventing, relieving or treating various carcinomas or RASopathy; a stereoisomer thereof; a solv...
|
|
WO/2023/115211A1 |
The invention is related to a method of treating a subject with acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma by administration of Compound (I), or a phar...
|
|
WO/2023/122784A2 |
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the...
|
|
WO/2023/120452A1 |
This SREBP-1 inhibitor has inhibitory activity against SREBP-1 and does not have inhibitory activity against SREBP-2, the SREBP-1 inhibitor containing, as an active ingredient, one or more compounds from among compounds represented by fo...
|
|
WO/2023/122154A1 |
A class of compounds useful in cancer therapy having formula (I): or an optically pure stereoisomer, pharmaceutically acceptable salt, or solvate thereof, wherein X is a nitrogen or an unsubstituted C1 group; Y is a nitrogen, a substitut...
|
|
WO/2023/115327A1 |
Disclosed are a pyrido ring compound, a preparation method therefor, an intermediate, a composition, and an application. The pyrido ring compound has a structure as shown in formula I, has JAK inhibitory activity, and can be used for tre...
|
|
WO/2023/115150A1 |
This invention relates to compounds of formula (X) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (X) to treat necroptosis and/or inhibit...
|
|
WO/2023/116888A1 |
A five- and six-membered compound, a preparation method, a pharmaceutical composition and the use. The five- and six-membered compound is a compound as shown in formula I or II, and has an inhibitory effect on FLT3 and/or IRAK.
|
